Neuroendocrine Carcinoma of the Bladder: A Case Report.
Pan GaoXinyu LiZiqiu HeYifan XuZhi ZhangPublished in: Research and reports in urology (2024)
Primary bladder large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive neoplasm with high recurrence rates and poor prognosis. Traditional management has heavily relied on radical cystectomy, which, despite its aggressiveness, often results in unsatisfactory outcomes. Emerging evidence suggests the potential for less invasive, bladder-sparing approaches, yet detailed reports and long-term outcomes remain scarce. We report a groundbreaking case of a 59-year-old male diagnosed with primary bladder LCNEC, managed through a pioneering bladder-sparing multimodal treatment. This novel strategy included transurethral resection followed by a tailored chemoradiation protocol, resulting in exceptional disease control and preservation of bladder function over a 20-month follow-up period, without evidence of recurrence. This case underscores the viability of bladder conservation strategies as a legitimate alternative to radical cystectomy for managing LCNEC, presenting a beacon of hope for patients wishing to preserve bladder functionality. It prompts a reevaluation of traditional treatment paradigms and advocates for further research into multimodal, organ-sparing approaches for this challenging malignancy.
Keyphrases
- spinal cord injury
- poor prognosis
- urinary tract
- long non coding rna
- randomized controlled trial
- end stage renal disease
- squamous cell carcinoma
- newly diagnosed
- robot assisted
- ejection fraction
- chronic kidney disease
- emergency department
- type diabetes
- stem cells
- radiation therapy
- pain management
- prognostic factors
- bone marrow
- skeletal muscle
- replacement therapy
- rectal cancer
- minimally invasive
- locally advanced
- high grade
- electronic health record
- muscle invasive bladder cancer